CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Mukul Agrawal Bought 4,63,023 Shares Of This Multibagger Pharma Stock; Board Announces Stock Split From Rs 5 to Rs 2, Check Record Date Inside
DSIJ Intelligence

Mukul Agrawal Bought 4,63,023 Shares Of This Multibagger Pharma Stock; Board Announces Stock Split From Rs 5 to Rs 2, Check Record Date Inside

The stock gave multibagger returns of 157.4 per cent from its 52-week low of Rs 270.05 per share and a whopping 2,570 per cent in 5 years.

Jagsonpal Pharmaceuticals Limited has announced plans to sub-divide or stock split its existing equity shares from a face value of Rs 5 to Rs 2 each. This move aims to increase liquidity and make the company's shares more accessible to smaller investors. The decision will be subject to the approval of the company's shareholders through a postal ballot. The record date for the subdivision or split is fixed as Wednesday, January 08, 2025.

An ace investor, Mukul Agrawal bought 4,63,023 shares or 1.75 per cent stake in September 2024.

Additionally, the company announced stellar Quarterly Results (Q2FY25) and half-yearly results (H1FY25). According to quarterly results, the net sales increased by 29.2 per cent to Rs 74.7 crore and net profit increased by 52 per cent to Rs 11.4 crore in Q2FY25 compared to Q2FY24. In its half-yearly results, the net sales increased by 15.3 per cent to Rs 136.1 crore and net profit increased by 12 per cent to Rs 16.8 crore in H1FY25 compared to H1FY24.

DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market. The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst the Top 5 brands in the molecule category, an extensive pan-India presence and an experienced sales team of over 900 professionals.

The company has a market cap of over Rs 1,800 crore and has been maintaining a healthy dividend payout of 54.5 per cent. The stock gave multibagger returns of 157.4 per cent from its 52-week low of Rs 270.05 per share and a whopping 2,570 per cent in 5 years. Investors should keep an eye on this small-cap stock.

Disclaimer: The article is for informational purposes only and not investment advice. 

Previous Article Drone Company Signs Memorandum of Understanding with Volatus Aerospace Inc
Next Article Rakesh Jhunjhunwala’s Close Associate Makes Fresh Entry in This Stock Under Rs 120, Gains Rs 1.09 Crore in a Day: Is This the Next Titan?
Print
769 Rate this article:
3.8
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR